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Most of the clinical research on coronavirus disease 2019 (COVID-2019) has focused on patients in Wuhan, 
Hubei, China. This study describes the clinical characteristics of COVID-19 patients outside of Hubei. Eighteen 
confirmed COVID-19 patients at Guizhou Provincial People's Hospital were included. They were divided into 
nonsevere and severe groups, and their epidemiological characteristics, demographics, clinical manifestations, 
and laboratory results were reviewed and compared. All patients were infected through human-to-human 
transmission, and 9 were imported cases. The clinical features were mainly cough (16 [89%]), fever (11 [61%]), 
and sputum production (9 [50%]). Most patients had bilateral pneumonia. There were significant differences in 
the level of lactate dehydrogenase (LDH) (179 [142-193] vs 289 [260.25-368.75]), level of serum ferritin (267.2 
[100.5-675.2] vs 614.85 [528.5-870.78]), lymphocyte count (1.52 [1.40-1.60] vs 0.59 [0.47- 1.05]), and CD cell count 
(1576 [1040-1696] vs 444 [312-592] CD3+ T cells, 692 [420-708] vs 144 [128-320] CD4+ T cells, 796 [632- 892] vs 
228 [152-284] CD8+ T cells) between the nonsevere group and the severe group (P <0.05). As of Feb. 11th, 9 
people had been discharged after treatment. This study suggests that COVID-19 cases often occur in clusters. 
Patients with severe COVID-19 had abnormalities in inflammation and immune indicators. Most patients outside 
Hubei had a good prognosis.  
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The Chinese Centers for Disease Control and Prevention 
reported an outbreak of cases of pneumonia in the Huanan 
Seafood Market, Wuhan city, Hubei Province, on December 
31, 2019[1]. The pneumonia cases were found to be caused by 
a new strain of coronavirus (SARS-CoV-2); this etiology was 
confirmed by the Ministry of Public Health of China on 
January 7th, 2020[2]. The cases were first reported in the areas 
surrounding the Huanan Seafood Market, and according to 
current epidemiological data, SARS-CoV-2 is transmitted 
between people[3-6]. As of March 10, more than 110 thousand 
cases had been reported globally, with more than 4000 deaths 
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have been reported. Cases of infection have spread all over the 
world[7]. The number of confirmed cases of coronavirus 
disease 2019 (COVID-19) has exceeded that of severe acute 
respiratory syndrome (SARS) in mainland China in 2002 and 
2003 and that of Middle East respiratory syndrome (MERS) 
in 2012[8, 9]. 
Some researchers found that the virus might have been 
transmitted from bats to humans through an intermediate 
host[10]. Infection with SARS-CoV-2 has several clinical 
manifestations in humans. The majority of the infected 
patients develop moderately severe clinical disease, while a 
certain number of patients develop severe disease 
characterized by acute lung injury (ALI) and acute respiratory 
distress syndrome (ARDS)[11,12]. The clinical features vary 
from mild to moderate symptoms to severe symptoms; the 
former are common in patients under 18 years of age, while 
the latter are more commonly observed in the elderly 
population[5,11,12]. Patients who have preexisting chronic 
diseases such as diabetes, obesity, cardiac failure and kidney 
failure are more likely to develop severe COVID-19[5,13,14]. 
The current studies have mainly been based on case studies in 
Wuhan city, and there have been few studies on the situation 
in Guizhou Province, as it is one of the provinces with the 
fewest infected patients in Southwest China. This article 
describes the epidemiological features of COVID-19 patients 
treated in Guizhou Provincial People's Hospital and the 
clinical features, countermeasures and therapeutic outcomes 
in patients with nonsevere and severe COVID-19. The aim is 
to provide additional information to improve the 
understanding of the COVID-19 pandemic. 
Materials and Methods 
This was a retrospective, single-center study. Data were 
obtained from confirmed COVID-19 patients admitted to 
Guizhou Provincial People's Hospital from January 29th, 2020, 
to February 11th, 2020. The diagnosis of COVID-19 was 
confirmed in all study patients by two positive nucleic acid 
tests. All the data of the included cases were shared with the 
WHO. The study was approved by Guizhou Provincial 
People's Hospital Ethics Committee. The need to obtain 
informed consent was waived because of the retrospective 
nature of the study and the use of anonymous clinical data. We 
obtained the epidemiological, demographic, clinical, 
laboratory and radiological characteristics; treatment 
information; and outcome data from patients’ medical records. 
Clinical outcomes were followed up to February 15th, 2020. 
All data were checked by two physicians (ZQ and LSY).         
Patients with suspected cases of COVID-19 were admitted and 
quarantined, and throat swab, alveolar lavage fluid, stool and 
breastmilk samples were collected and sent to the Chinese 
Centers for Disease Control and Prevention for the detection 
of SARS-CoV-2 with a quantitative polymerase chain reaction 
assay. Sputum or endotracheal aspirates were obtained at 
admission for the identification of pathogenic bacteria or fungi. 
Additionally, all patients underwent chest CT. 
The epidemiological data (i.e., history of travel to Wuhan 
or close contact with confirmed patients); demographics; signs 
and symptoms on admission; comorbidities; laboratory results; 
chest CT findings; treatment received for COVID-19; and 
clinical outcomes were analyzed. 
Statistical Analysis 
Continuous variables are expressed as the medians (IQRs) 
and were compared with the Mann-Whitney U test; 
categorical variables are expressed as numbers (%) and were 
compared by χ² tests between the severe and nonsevere groups. 
A P value less than 0.05 was considered statistically 
significant. Statistical analyses were conducted using SPSS 
software, version 25.0. 
Results 
By February 11, 2020, 18 admitted hospital patients had 
been identified as having laboratory-confirmed COVID-19 in 
Guiyang. Among these patients, 9 had a history of travel to 
epidemic areas, and 8 out of those 9 patients were local 
citizens who had returned home from Hubei Province, 
including a household of 3 family members, whereas the other 
patient was a citizen of Wuhan city. Two of the 9 imported 
patients were a 50-day-old infant and a 4-year-old child. The 
other 9 patients were infected via close contact with 
individuals with confirmed COVID-19. Three of the 9 were 
infected while sharing meals with family members (Figure 1). 
Family gatherings were the source of infection among most of 
the patients. The average incubation period was generally 11.5 
(5.5-14) days. 
Of the 18 patients, 7 (38.9%) were diagnosed with severe 
COVID-19 because their arterial oxygen tension (PaO2) over 
inspiratory oxygen fraction (FIO2) was less than 300 mmHg 
or their oxygen saturation level was less than 93%. Only 3 
severe COVID-19 patients had a history of travel to an 
epidemic area. The median age of all the patients was 40.5 
(23–55) years (34 [15-58] years in the nonsevere group vs 44 
[37-54] years in the severe group [P=0.007]). Two children 
and two elderly people were in the nonsevere group, while the 
age of patients in critical condition ranged from 19 to 60 years. 
Eight (44%) of the infected patients were men; less than half 
had underlying diseases (7 [39%]), including hypertension (5 
[28%]), diabetes (1 [5.5%]), and pulmonary disease (1 [5.5%]). 
There were no significant differences between the two groups 
of patients with regard to comorbidities. The main symptoms 
at the onset of illness were cough (16 [89%]), fever (11 [61%]),  




Figure 1. Sources of infection for 18 COVID-19 patients. (M=male, F=female) 
 
and sputum production (9 [50%]); other symptoms were 
myalgia or fatigue (4 [22%]), shortness of breath (4 [22%]), 
chills (2 [11%]), nausea and vomiting (2 [11%]), sore throat 
(1 [5.6%]), dizziness (1 [5.6%]) and rhinorrhea (1 [5.6%]). In 
the severe group, all the patients (100%) had fever, while 4 
(36%) patients in the nonsevere group had fever (P=0.013) 
(Table 1). 
The neutrophil counts in the two groups remained normal; 
however, the lymphocyte count in the severe group was 0.59 
(0.47-1.05), which was obviously lower than the normal range, 
whereas the lymphocyte count in the nonsevere group was 
1.52 (1.40-1.60). There was a significant difference (P=0.016) 
between the two groups. The monocyte and blood platelet 
counts, as well as the coagulation function and hepatorenal 
function, remained normal. No differences were observed 
between the two groups. However, the LDH levels were 
elevated to varying degrees in all patients, and the levels were 
particularly elevated in the severe group (179 [142-193] in the 
nonsevere group vs 289 [260.25-368.75] in the severe group) 
(P=0.027). The levels of PCT, ESR, serum ferritin, and C-
reactive protein were also elevated in the severe group, and 
there was a significant difference in the serum ferritin levels 
between the nonsevere and severe groups (267.2 [100.5-675.2] 
in the nonsevere group vs 614.85 [528.5-870.78] in the severe 
group) (P=0.028). The  CD3+ T cell (1576 [1040-1696] in 
the nonsevere group vs 444 [312-592] in the severe group), 
CD4+ T cell (692 [420-708] in the nonsevere group vs 144 
[128-320] in the severe group) and CD8+ T cell (796 [632-
892] in the nonsevere group vs 228 [152-284] in the severe 
group) counts were lower than normal ranges in the severe 
group, and the counts were significantly different between the 
severe and nonsevere groups (P＜0.000). Because the results  
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Table 1. Demographics and baseline characteristics of COVID-19 patients. 






Age, years# 40.5 (23-55) 34 (15-58) 44 (37-54) 0.007 
≤7 2 (11%) 2 (18%) 0 0.497 
7-18 2 (11%) 2 (18%) 0 0.497 
19-60 12 (67%) 5 (45%) 7 (100%) 0.038 
≥60 2 (11%) 2 (18%) 0 0.497 
Sex     
Men 8 (44%) 4 (36%) 4 (57%) 0.63 
Women 10 (56%) 7(64%) 3 (43%) 0.63 
History of travel to an epidemic 
area 
9 (50%) 6 (54.5%) 3 (42.9%) 0.5 
Close-contact with individuals with 
confirmed COVID-19 
9 (50%) 5 (45.5%) 4 (57.1%) 0.5 
Any comorbidity 7 (39%) 4 (36%) 3 (43%) 0.583 
Hypertension 5 (28%) 3 (17%) 2 (29%) 0.676 
Diabetes 1 (5.5%) 1 (5.6%) 0 0.611 
Pulmonary disease 1 (5.5%) 0 1 (14%) 0.389 
Signs and symptoms at admission     
Cough 16 (89%) 10 (91%) 6 (86%) 0.641 
Fever# 11 (61%) 4 (36%) 7 (100%) 0.013 
Sputum production 9 (50%) 4 (36%) 5 (71%) 0.335 
Shortness of breath 4 (22%) 1 (9%) 3 (43%) 0.245 
Myalgia or fatigue 4 (22%) 1 (9%) 3 (43%) 0.245 
Nausea and vomiting 2 (11%) 1 (9%) 1 (14%) 0.641 
Chills 2 (11%) 1 (9%) 1 (14%) 0.641 
Sore throat 1 (5.6%) 1 (9%) 0 0.611 
Dizziness 1 (5.6%) 0 1 (14%) 0.389 
Diarrhea 1 (5.6%) 0 1 (14%) 0.389 
Rhinorrhea 1 (5.6%) 1 (9%) 0 0.611 
More than one sign or symptom 14 (78%) 7 (64%) 7 (100%) 0.119 
#: The value in the two groups was considered statistically significant. 
 
of the blood tests were substantially different between children 
and adults, the analysis excluded the two young children. No 
abnormalities were observed on chest CT in 2 of the patients, 
while patchy inflammatory exudation was observed in the 
other patients. Nine (39%) patients had bilateral pneumonia, 
and 1 (5.6%) patient had unilateral pneumonia. Eight (44%) 
patients had multiple areas of mottling and ground glass 
opacity (Figure 2). In the severe group, most patients had 
multiple areas of mottling and ground glass opacity (5 
[71.4%]). Nucleic acid testing of the throat swab was negative, 
while nucleic acid testing of bronchoalveolar lavage fluid was 
positive in one patient with severe COVID-19. Two patients 
in the nonsevere group had positive results for nucleic acid in 
feces samples. One lactating female patient was identified as 
being infected on the same day as was her 50-day-old daughter. 
The nucleic acid testing of her breast milk was negative (Table 
2). All the bacteria and fungi cultures from the patients were 
also negative. 
All patients were isolated in the hospital. All of them 
received antiviral treatment, including oseltamivir (75 mg 
every 12 h, orally), Arbidol (200 mg every 8 h, orally), or 
lopinavir and ritonavir tablets (500 mg twice daily, orally). 
Most patients (17 [94.4%]) were given antibiotic treatment; 7 
(38.9%) patients were given antifungal therapy. Six (85.7%) 
of the patients in the severe group used corticosteroids, while 
2 (18.2%) of the patients in the nonsevere group used  




Figure 2. Chest CT images. These chest CT images were obtained from a 54-year-old female 
patient. On February 5, large ground glass opacities were observed on both sides of the lung fields, 
mostly beneath the pleura. On February 8, the lesion area and density had increased. On February 
11, the lesion area had increased, and consolidation was observed. The ground glass opacity in the 
upper right lung started to be assimilated. By February 14, more of the lesion area had been 
assimilated, and the rest had developed into fibrosis. 
 
corticosteroids (P=0.013). Twelve (66.7%) patients required 
oxygen therapy, of whom 3 (42.9%) patients in the severe 
group required noninvasive ventilation or high-flow nasal 
cannula. Most of the patients were given drugs to improve 
their immunity. Targeted traditional Chinese medicine was 
also administered to all the patients. By February 15, 2020, 9 
(5 in the nonsevere group, 4 in the severe group) patients had 
been discharged from the hospital (Table 3). Their average 
period of treatment in the hospital was 10 (5.5-13.5) days. 
Discussion 
This essay is a cross-sectional study of the COVID-19 cases 
in Guizhou Province, the least affected region in the 
Southwest China. Eighteen patients with confirmed cases 
treated in Guizhou Province People's Hospital were 
investigated. The epidemiological, demographic, and clinical 
characteristics; laboratory test results; treatments; and 
prognoses were compared between the patients in the 
nonsevere and severe groups. 
We find that the patients are identified as the second and 
third generation patients. Half of them had a history of travel 
to an epidemic area and were infected at family gatherings. 
The COVID-19 outbreak started during the Chinese Spring 
Festival. A large number of migrant workers traveled to gather 
with family members. Thus, the location and the timing were 
critical factors that made it difficult to prevent the spread of 
the infection. The incubation period of the disease was 11.5 
days in this study, which is similar to the 14-day incubation 
period reported previously[5]. Moreover, most of the patients 
were between the ages of 19 and 60 years. This group is more 
likely to be infected because they are more likely to travel 
within and between regions than children and seniors. We also 
found no obvious predominance of one sex among the patients, 
which conflicts with the reports that stated that males are more 
likely to be infected than females[5,15]. Therefore, future 
investigations should have larger sample sizes. Patients with 
other chronic diseases accounted for a small proportion of the 
whole sample of patients in this study, and there were slight 
differences among the patients before they developed either 
nonsevere or severe COVID-19. Therefore, in addition to 
preexisting chronic diseases, other factors, such as immunity  
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Table 2. Laboratory results of COVID-19 patients. 









White blood cell count, × 10⁹/L 3.5-9.5 4.35 (3.29-6.65) 4.35 (3.59-6.23) 4.78 (2.70-8.11) 0.96 
Neutrophil count, × 10⁹/L 1.8-6.3 2.46 (1.87-4.58) 2.31 (1.66-4.21) 2.79 (1.99-7.22) 0.5 
Lymphocyte count, × 10⁹/L# 1.1-3.2 1.41 (0.59-1.56) 1.52 (1.40-1.60) 0.59 (0.47-1.05） 0.016 
Monocyte count, × 10⁹/L 0.1-0.6 0.37 (0.3-0.53) 0.41 (0.36-0.57) 0.27 (0.12-0.39) 0.097 
Platelet count, × 10⁹/L 125-350 229 (189-290) 218 (177-304) 246.5 (185.5-286) 0.84 
Prothrombin time, s 9.2-12.2 10.6 (10.2-11.3) 10.5 (10.3-11.3) 10.8 (10-11.3) 0.98 
Activated partial thromboplastin time, s 21.1-36.5 26.1 (24.2-28.9) 28.1 (24.2-30.0) 25.2 (24.2-27.9) 0.432 
D-dimer, mg/L 0-1.5 0.43 (0.22-0.62) 0.34 (0.19-0.55) 0.51 (0.38-0.76) 0.139 
Albumin, g/L 40-55 40.3 (37.4-41.7) 40.3 (37.4-43.5) 39.25 (36.1-40.7) 0.24 
Alanine aminotransferase, U/L 9-50 31 (12-43.5) 15 (11-42) 33 (17.3-55.3) 0.287 
Aspartate aminotransferase, U/L 15-40 25 (14.5-35) 15 (13-32) 27.5 (24.8-49.3) 0.086 
Total bilirubin, mmol/L 3.4-20.5 15.1 (12.1-18.4) 12.7 (9.6-18.2) 16.85 (13.9-19.5) 0.312 
Creatine kinase, U/L 50-310 70 (48.3-190.8) 49 (40-107) 121 (64-287.5) 0.261 
Creatinine, μmol/L 57-97 62 (56.5-76.5) 72 (57-80) 60 (55.8-82.3) 0.887 
Blood urea nitrogen, mmol/L 3.1-8 3.91 (3.3-6) 3.91 (2.9-4.6) 4.65 (3.3-6.7) 0.233 
Lactate dehydrogenase, U/L# 120-250 231 (175.5-313) 179 (142-193) 289 (260.3-368.8) 0.027 
Procalcitonin, ng/mL 0-0.046 0.04 (0.02-0.07) 0.03 (0.02-0.06) 0.065 (0.04-0.09) 0.582 
Interleukin-6, pg/mL 0-7 2.95 (1.5-6.89) 2.95 (1.5-5.97) 3.9 (1.5-22.67) 0.888 
Erythrocyte sedimentation rate mm/h; 2-20.9 42 (19-63) 41 (10-66) 45 (33.3-63.5) 0.689 
Serum ferritin, ng/mL# 30-400 
548.8 (192.3-
682.8) 
267.2 (100.5-675.2) 614.9 (528.5-870.8) 0.028 
C-reactive protein, mg/L 0-5 7.16 (1.65-21.91) 2.61 (1.13-15.53) 14.57 (5.53-34.51) 0.642 
CD3+T cell count# 770-2860 1576 (792-2260) 1576 (1040-1696) 444 (312-592) 0.000 
CD4+T cell count# 500-1440 692 (384-924) 692 (420-708) 144 (128-320) 0.000 
CD8+T cell count# 238-1250 796 (540-892) 796 (632-892) 228 (152-284) 0.000 
CD4:CD8 1-2.47 1.28 (0.83-1.50) 1.01 (0.78-2.31) 1.37 (0.66-1.42) 0.931 
Chest CT findings      
Normal  2 (11%) 2 (18%) 0 0.497 
Unilateral pneumonia  1 (5.6%) 1 (9%) 0 0.611 
Bilateral pneumonia  7 (39%) 5 (45%) 2 (28.6%) 0.637 
Multiple mottling and ground-glass opacity  8 (44%) 3 (27%) 5 (71.4%) 0.145 
RT-PCR testing for SARS-CoV-2      
Oropharyngeal swab  17 (94.4%) 11 (100%) 6 (85.7%) NA 
Stool  2 (11%) 2 (18.2%) 0 NA 
Alveolar lavage  1 (5.6%) 0 1 (14.3%) NA 
Breastmilk  0 0 0 NA 
#: The value in the two groups was considered statistically significant. 
 
and inflammation, should be examined when conducting 
research on the development of severe COVID-19. In this 
cohort, the main symptoms were cough, fever, and sputum 
production. Bilateral ground glass opacities were observed on 
chest CT. Similar symptoms and CT results were observed in 
SARS and MERS patients[13,16]. A few patients had digestive 
symptoms, including nausea, vomiting and diarrhea, which 
were also seen in MERS and SARS patients. However, the  
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 P Value 
Treatment     
Antiviral therapy 18 (100%) 11 (100%) 7 (100%) NA 
Antibiotic therapy 17 (94.4%) 10 (90.9%) 7 (100%) 0.611 
Antifungal therapy 7 (38.9%) 3 (7.2%) 4(57.1%) 0.332 
Use of corticosteroids# 8 (44.4%) 2 (18.2%) 6 (85.7%) 0.013 
Oxygen support     
Nasal cannula 12 (66.7%) 5 (45.5%) 7 (100%) 0.038 
Noninvasive ventilation or high-flow nasal cannula# 3 (16.7%) 0 3 (42.9%) 0.043 
Enhanced immunotherapy 12 (66.7%) 6 (54.5%) 6 (85.7%) 0.316 
Chinese medicine therapy 18 (100%) 11 (100%) 7 (100%) NA 
Clinical outcome     
Remained in hospital 9 (50%) 6 (54.5%) 3 (42.9%) 0.5 
Discharged 9 (50%) 5 (45.5%) 4 (57.1%) 0.5 
Died 0 0 0 NA 
#: The value in the two groups was considered statistically significant. 
 
likelihood of developing digestive symptoms is relatively 
lower in COVID-19 patients[13]. 
Previous research on SARS-CoV and MERS-CoV showed 
that humans could be affected by direct and indirect damage. 
Direct damage refers to the damage inflicted on the target cells 
infected by virus, while indirect damage is caused by the 
immune response, circulatory dysfunction and anoxia. It is 
thought that the pathological effects on cells due to viral 
infection and the host immunoreactions to viruses are critical 
in evaluating the severity of the disease[17]. SARS-CoV, 
MERS-CoV and SARS-CoV-2 all cause acute respiratory 
disease with symptoms such as low-grade fever, cough and 
ALI, and ARDS or death can develop[18-20]. The disease is 
characterized by a high viral load and symptoms such as fever 
and cough in the early stage. Then, patients develop symptoms 
of pneumonia as the viral titer decreases[19]. A minority of the 
patients developed ARDS and multiple organ failure, resulting 
in death. As the viral titer continuously decreased, the 
worsening of a patient’s condition is thought to be the result 
of intense immune and inflammatory responses. According to 
recent cohort studies, the ESR and the levels of serum ferritin, 
CRP, PCT, and LDH are direct or indirect indicators of the 
degree of inflammation. The levels of all these indicators were 
higher in the severe group than in the nonsevere group. The 
levels of serum ferritin and LDH were substantially higher in 
the severe group than in the nonsevere group. The 
inflammatory cytokine storm is a critical factor that results in 
severe consequences. Moreover, the specificity of the 
responses of T cells to the SARS-CoV-2 infection is the key 
to eliminating the virus and preventing more damage to the 
host[21,22]. Furthermore, T cells can also suppress innate 
immunity if the response is excessive[23,24]. This study showed 
that the counts of the peripheral blood lymphocytes, CD3+ T 
cells, CD4+ T cells and CD8+ T cells were lower than the 
normal ranges in the severe group and were significantly 
different between the severe and the nonsevere groups. This 
shows that T cell apoptosis causes lymphocyte exhaustion, 
and a decline in the peripheral blood lymphocyte count 
indicates the development of severe disease and possible 
mortality. T cells, especially CD4+ T cells and CD8+ T cells, 
combat the viral infection by producing an inflammatory 
cytokine storm[25]. CD4+ T cells induce the production of 
specific antibodies against the virus by activating T-dependent 
B cells. CD8+ T cells, which are cytotoxic agents, kill infected 
cells. CD8+ T cells account for 80% of the inflammatory cells 
infiltrating the pulmonary interstitium and eliminate SARS-
CoV-2 in the infected cells, which will damage host immunity. 
CD4+ T cell exhaustion is related to the reduction in the 
lymphocyte count in the lung and the generation of 
neutralizing antibodies and cytokines. Exhaustion delays the 
elimination of the virus and leads to immune-mediated 
interstitial pneumonia[26]. Based on the positive nucleic acid 
test results in throat swab, bronchoalveolar lavage fluid and 
feces samples, the virus is transmitted through the respiratory 
and digestive tracts. There is no evidence of transmission via 
breast milk, as the nucleic acid tests of breast milk were 
negative. 
Prompt treatment is critical in the early stage of COVID-19; 
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however, no effective antiviral drugs have been developed for 
clinical use. Based on the positive clinical effects of 
lopinavir/ritonavir on SARS and the mildly curative effects of 
Arbidol in the early stage, the combined use of 
lopinavir/ritonavir and Arbidol is now the main antivirus 
treatment[27]. While the remdesivir was very effective against 
MERS-CoV, and one COVID-19 patient obtained a satisfying 
result after taking remdesivir, remdesivir is still undergoing 
clinical trials in Wuhan[27-29]. The extensive use of remdesivir 
has not been reported thus far. Other antibacterial and 
antifungal drugs have been administered to some patients 
prophylactically. The short-term administration of low doses 
of glucocorticoids to patients with severe disease is 
controversial. Some believe that glucocorticoids could delay 
the elimination of the virus and might not have positive effects 
on the resolution of pulmonary inflammation[30]. For people 
with low immunity, the use of thymosin has been suggested to 
reduce the time needed to eliminate the virus and prevent 
patients from developing more severe disease. The 
concomitant use of targeted Chinese traditional medicine and 
Western medicine is encouraged. Noninvasive ventilation 
treatment is provided for patients with acute respiratory 
distress. 
Meanwhile, this study had two limitations. First, a larger 
sample size is needed. Given the current situation, this 
research excluded suspected infections and people under 
medical observation; therefore, only 18 patients with 
confirmed cases of COVID-19 in Guizhou Province were 
included. Second, due to the small sample size, it was difficult 
to build a model based on the relevant factors to predict the 
prognosis. However, the data provided in this article could 
contribute to the understanding and evaluation of the 
epidemiological and clinical features of patients in places 
outside of Wuhan. 
COVID-19 often develops in family clusters and is 
transmitted through the respiratory and digestive tracts. 
Patients with severe COVID-19 have abnormally high levels 
of inflammation and reduced immunity. More importantly, 
most of the patients recovered well after receiving appropriate 
treatment. 
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